Allelic losses in neurofibromatosis 2-associated meningiomas

Journal of Neuropathology and Experimental Neurology

Volumn 59, Issue 6, 2000, Pages 504-512

  Lamszus, Katrin ^a   Vahldiek, Felix ^a   Mautner, Victor Felix ^b   Schichor, Christian ^c   Tonn, Jörg ^c   Stavrou, Dimitrios ^a   Fillbrandt, Regina ^a   Westphal, Manfred ^a   Kluwe, Lan ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Klinik Ochsenzoll   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Loss of heterozygosity; Meningeal tumor; Microsatellites; Mutation; Proliferation

Indexed keywords

ADOLESCENT; ADULT; ALLELE; ARTICLE; CANCER DIAGNOSIS; CANCER GENETICS; CANCER GRADING; CHILD; CLINICAL ARTICLE; DISEASE ASSOCIATION; FEMALE; GENE DELETION; GENE LOCATION; GENE LOCUS; GENE LOSS; GENE MUTATION; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; MALE; MENINGIOMA; NEUROFIBROMATOSIS; PRIORITY JOURNAL;

EID: 0034120650     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnen/59.6.504     Document Type: Article

References (44)

1. Evans DGR, Huson SM, Donnai D, et al. A clinical study of type 2 neurofibromatosis. Q J Med 1992;84:603-18
2. Mautner VF, Tatagiba M, Guthoff R, Samii M, Pulst SM. Neurofibromatosis 2 in the pediatric age group. Neurosurgery 1993;33: 92-96
3. Mautner VF, Lindenau M, Baser ME, et al. The neuroimaging and clinical spectrum of neurofibromatosis 2. Neurosurgery 1996;38: 880-86
4. Lekanne Deprez RH, Bianchi A, Groen NA, et al. Frequent NF2 gene transcript mutations in sporadic meningiomas and vestibular schwannomas. Am J Hum Genet 1994;54:1022-29
5. Mérel P, Hoang-Xuan K, Sanson M, et al. Predominant occurrence of somatic mutations of the NF2 gene in meningiomas and schwannomas. Genes Chromosom Cancer 1995;13:211-16
6. Wellenreuther R, Kraus JA, Lenartz D, et al. Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma. Am J Pathol 1995;146:827-32
7. Joseph JT, Lisle DK, Jacoby LB, et al. NF2 gene analysis distinguishes hemangiopericytoma from meningioma. Am J Pathol 1995;147:1450-55
8. Weber RG, Boström J, Wolter M, et al. Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: Toward a genetic model of meningioma progression. Proc Natl Acad Sci USA 1997;94:14719-24
9. Simon M, von Deimling A, Larson JJ, et al. Allelic losses on chromosomes 14, 10, and 1 in atypical and malignant meningiomas: A genetic model of meningioma progression. Cancer Res 1995;55: 4696-4701
10. Lamszus K, Kluwe L, Matschke J, Meissner H, Laas R, Westphal M. Allelic losses at 1p, 9q, 10q, 14q, and 22q in the progression of aggressive meningiomas and undifferentiated meningeal sarcomas. Cancer Genet Cytogenet 1999;110:103-10
11. Leone PE, Bello MJ, de Campos JM, et al. NF2 gene mutations and allelic status of 1p, 14q and 22q in sporadic meningiomas. Oncogene 1999;18:2231-39
12. Antinheimo J, Haapasalo H, Haltia M, et al. Proliferation potential and histological features in neurofibromatosis 2-associated and sporadic meningiomas. J Neurosurg 1997;87:610-14
13. Mc Lendon RE, Tien RD. Genetic syndromes associated with tumors and/or hamartomas. In: Bigner DD, McLendon RE, Bruner JM, eds. Russell and Rubinstein's pathology of tumors of the nervous system, 6th edition. London: Arnold, 1998:371-418
14. Gutman DH, Aylsworth A, Carey JC, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. J Am Med Assoc 1997;278:51-57
15. Kleihues P, Burger PC, Scheithauer BW. Histological typing of tumours of the central nervous system. Berlin: Springer, 1993
16. Perry A, Scheithauer BW, Stafford SL, Lohse CM, Wollan PC. "Malignancy" in meningiomas. Cancer 1999;85:2046-56
17. Kluwe L, MacCollin MM, Tatagiba M, et al. Phenotypic variablity associated with 14 splice-site mutations in the NF2 gene. Am J Med Genet 1998;77:228-33
18. Kluwe L, Mautner VF. Mosaicism in sporadic neurofibromatosis 2 patients. Hum Mol Genet 1998;7:2051-55
19. Kluwe L, Bayer S, Baser ME, et al. Identification of NF2 germ-line mutations and comparison with neurofibromatosis 2 phenotypes. Hum Genet 1996;98:534-38
20. Zang KD, Singer H. Chromosomal constitution of meningiomas. Nature 1967;216:84-85
21. Westphal M, Hänsel M, Kunzmann R, Hölzel F, Herrmann HD. Spectrum of karyotypic aberrations in cultured human meningiomas. Cytogenet Cell Genet 1989;52:45-49
22. Ruttledge MH, Xie YG, Han FY, et al. Deletion on chromosome 22 in sporadic meningiomas. Genes Chromosomes Cancer 1994;10: 122-30
23. Jiménez-Lara AM, Rey JA, Bello MJ, et al. Cytogenetics of human meningiomas: An analysis of 125 cases. Cancer Genet Cytogenet 1992;63:174
24. Bello MJ, Leone PE, Nebreda P, et al. Allelic status of chromosome 1 in neoplasms of the nervous system. Cancer Genet Cytogenet 1995:160-64
25. Rempel SA, Schwechheimer K, Davis RL, Cavenee WK, Rosenhlum ML. Loss of heterozygosity for loci on chromosome 10 is associated with morphologically malignant meningioma progression. Cancer Res 1993;53:2386-92
26. Boström J, Cobbers JMJL, Wolter M, et al. Mutation of the PTEN (MMAC1) tumors suppressor gene in a subset of glioblastomas but not in meningiomas with loss of chromosome arm 10q. Cancer Res 1998;58:29-33
27. Peters N, Wellenreuther R, Rollbrocker B, et al. Analysis of the PTEN gene in human meningiomas. Neuropathol Appl Neurobiol 1998;24:3-8
28. Sulman EP, Dumanski JP, White PS, et al. Identification of a consistent region of allelic loss on 1p32 in meningiomas: Correlation with increased morbidity. Cancer Res 1998;58:3226-30
29. Ruttledge MH, Rangaratnam S, Sarrazin J, et al. Evidence for the complete inactivation of the NF2 gene in a majority of sporadic meningiomas. Nature Genet 1994;6:180-84
30. De Vitis LR, Tedde A, Vitelli F, et al. Screening for mutations in the neurofibromatosis type 2 (NF2) gene in sporadic meningiomas. Hum Genet 1996;97:632-37
31. Mérel P, Khe HX, Sanson M, et al. Screening for germ-line mutations in the NF2 gene. Genes Chromosom Cancer 1995;12:117-27
32. Parry DM, MacCollin MM, Kaiser-Kupfer MI, et al. Germ-line mutations in the neurofibromatosis 2 gene: Correlations with disease severity and retinal abnormalities. Am J Hum Genet 1996;59: 529-39
33. Ruttledge MH, Andermann AA, Phelan CM, et al. Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease. Am J Hum Genet 1996;59:331-42
34. Boström J, Mühlbauer A, Reifenberger G. Deletion mapping of the short arm of chromosome 1 identifies a common region of deletion distal to D1S496 in human meningiomas. Acta Neuropathol 1997;94:479-85
35. Tse JYM, Ng HK, Lau KM, Lo KW, Poon WS, Huang DP. Loss of heterozygosity of chromosome 14q in low- and high-grade meningiomas. Hum Pathol 1997;28:779-85
36. Menon AG, Rutter JL, von Sattel JP, et al. Frequent loss of chromosome 14 in atypical and malignant meningioma: Identification of a putative 'tumor progression' locus. Oncogene 1997;14:611-16
37. Perry A, Stafford SL, Scheithauer BW, Suman VJ, Lohse CM. The prognostic significance of MIB-1, p53, and DNA flow cytometry in completely resected primary meningiomas. Cancer 1998;82: 2262-69
38. Deen HG, Scheithauer BW, Ebersold MJ. Clinical and pathological study of meningiomas of the first two decades of life. J Neurosurg 1982;56:317-22
39. Nakasu S, Nakajima M, Matsumura K, Nakasu Y, Handa J. Meningioma: Proliferating potential and clinicoradiological features. Neurosurgery 1995;37:1049-55
40. Karamitopoulou E, Perentes E, Diamantis I, Maraziotis T. Ki-67 immunoreactivity in human central nervous system tumors: A study with MIB 1 monoclonal antibody on archival material. Acta Neuropathol 1994;87:47-54
41. Kolles H, Niedermayer I, Schmitt C, et al. Triple approach for diagnosis and grading of meningiomas: Histology, morphometry of Ki-67/Feulgen stainings, and cytogenetics. Acta Neurochir 1995;137:174-81
42. Ohkoudo M, Sawa H, Shiina Y, et al. Morphometrical analysis of nucleolin immunohistochemistry in meningiomas. Acta Neuropathol 1996;92:1-7
43. Maier H, Wanschitz J, Sedivy R, Rösslert K, Öfner D, Budka H. Proliferation and DNA fragmentation in meningioma subtypes. Neuropathol Appl Neurobiol 1997;23:496-506
44. Karamitopoulou E, Perentes E, Tolnay M, Probst A. Prognostic significance of MIB-1, p53, and bcl-2 immunoreactivity in meningiomas. Hum Pathol 1998;29:140-45